Bionet (1784) - Total Assets
Based on the latest financial reports, Bionet (1784) holds total assets worth NT$3.10 Billion TWD (≈ $97.62 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Bionet book value and equity for net asset value and shareholders' equity analysis.
Bionet - Total Assets Trend (2017–2024)
This chart illustrates how Bionet's total assets have evolved over time, based on quarterly financial data.
Bionet - Asset Composition Analysis
Current Asset Composition (December 2024)
Bionet's total assets of NT$3.10 Billion consist of 63.4% current assets and 36.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.7% |
| Accounts Receivable | NT$279.97 Million | 8.9% |
| Inventory | NT$81.34 Million | 2.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Bionet's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 1784 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bionet's current assets represent 63.4% of total assets in 2024, an increase from 44.2% in 2017.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, up from 6.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 8.9% of total assets.
Bionet Competitors by Total Assets
Key competitors of Bionet based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs29.59 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.94 Million |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
|
Indonesia | Rp304.08 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Bionet - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.20 | 4.25 | 3.40 |
| Quick Ratio | 3.94 | 4.04 | 3.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.45 Billion | NT$1.36 Billion | NT$534.41 Million |
Bionet - Advanced Valuation Insights
This section examines the relationship between Bionet's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.66 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 34.4% |
| Total Assets | NT$3.16 Billion |
| Market Capitalization | $115.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bionet's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bionet's assets grew by 34.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bionet (2017–2024)
The table below shows the annual total assets of Bionet from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.16 Billion ≈ $99.44 Million |
+34.39% |
| 2023-12-31 | NT$2.35 Billion ≈ $74.00 Million |
+27.73% |
| 2022-12-31 | NT$1.84 Billion ≈ $57.93 Million |
+3.07% |
| 2021-12-31 | NT$1.78 Billion ≈ $56.20 Million |
+2.84% |
| 2020-12-31 | NT$1.73 Billion ≈ $54.65 Million |
-1.51% |
| 2019-12-31 | NT$1.76 Billion ≈ $55.49 Million |
-1.24% |
| 2018-12-31 | NT$1.78 Billion ≈ $56.18 Million |
-2.28% |
| 2017-12-31 | NT$1.82 Billion ≈ $57.50 Million |
-- |
About Bionet
BIONET Corp. engages in the cell therapy business in Taiwan and internationally. The company offers stem cell banking services, such as stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC and immune cells; and genetic testing services. It also provides storage and application of hematopoietic stem cells; regenerative medicine, analytical testing… Read more